All Stories

Buy Amryt Pharma at a 24.5p offer - target to sell 30p+

Tom Winnifrith
Wednesday 13 September 2017

Amryt  Pharma (AMYT) has announced results for the six months ended 30 June 2017. There were no great shocks  the buy case is compelling and low risk - my target, for shares I admit to owning, is very conservative. Others are twice as ambitious or more!

on ShareProphets | Comments

Filed under:

About Tom Winnifrith
Bio
Tom Winnifrith is the editor of TomWinnifrith.com. When he is not harvesting olives in Greece, he is (planning to) raise goats in Wales.
Twitter
@TomWinnifrith
Email
[email protected]
Recently Featured on ShareProphets
Sign up for my weekly newsletter








Required Reading

Recent Comments


I also read